Kazem Kazempour

Use of a patch containing heat-labile toxin from Escherichia coli against travellers' diarrhoea: a phase II, randomised, double-blind, placebo-controlled field trial

Sarah A. Frech, Herbert L. DuPont, A. Louis Bourgeois et al. · The Lancet · 2008 · 204 citations

Life Sciences, Infectious Diseases, Microbiology +12

CCR5 inhibition in critical COVID-19 patients decreases inflammatory cytokines, increases CD8 T-cells, and decreases SARS-CoV2 RNA in plasma by day 14

Bruce K. Patterson, Harish Seethamraju, Kush Dhody et al. · International Journal of Infectious Diseases · 2020 · 147 citations · Full text

Life Sciences, Immunology, Infectious Diseases +17

Low-dose paroxetine 7.5 mg for menopausal vasomotor symptoms

James A. Simon, David Portman, Andrew M. Kaunitz et al. · Menopause The Journal of The North American Menopause Society · 2013 · 144 citations

Medicine, Pharmacology, Pharmacotherapy +16

Transcutaneous immunization with the heat-labile toxin (LT) of enterotoxigenic Escherichia coli (ETEC): Protective efficacy in a double-blind, placebo-controlled challenge study

Robin McKenzie, A. Louis Bourgeois, Sarah A. Frech et al. · Vaccine · 2007 · 125 citations

Life Sciences, Immunology, Immunization +14

The EUPHRATES trial (Evaluating the Use of Polymyxin B Hemoperfusion in a Randomized controlled trial of Adults Treated for Endotoxemia and Septic shock): study protocol for a randomized controlled trial

David J. Klein, Debra Foster, Christa Schorr et al. · Trials · 2014 · 109 citations · Full text

Medicine, Internal Medicine, Pharmacology +12